Difference between revisions of "Non-small cell lung cancer, MET-mutated"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...") |
m (regimen/variant) |
||
Line 15: | Line 15: | ||
=Metastatic disease= | =Metastatic disease= | ||
− | ==Capmatinib {{#subobject: | + | ==Capmatinib {{#subobject:791280|Regimen=1}}== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- |
Revision as of 20:43, 6 May 2020
Section editor | |
---|---|
Travis Osterman, DO, MS Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Metastatic disease
Capmatinib
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence |
---|---|---|
Wolf et al. 2019 (GEOMETRY mono-1) | Phase II |
Biomarker Eligibility Criteria
- Biomarker: MET exon 14 skipping
Chemotherapy
- Capmatinib (Tabrecta) 400 mg PO twice per day with or without food
Continued indefinitely
References
- GEOMETRY mono-1: Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. link to abstract contains verified protocol DOI